{
  "ticker": "RAC",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02968033",
  "id": "02968033",
  "pages": 3,
  "price_sensitive": true,
  "date": "20250710",
  "time": "0907",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250710/pdf/06lnpsh6p4ck20.pdf",
  "summary": "- **Ethics approval received** for Phase 1 RC220 trial at Prince of Wales Hospital and Queen Mary Hospital (Hong Kong).  \n- **Formal Department of Health (DoH) approval** secured for Queen Mary Hospital; expected soon for Prince of Wales Hospital.  \n- **Trial enrollment timeline**: Site activations expected late July\u2013mid-August 2025, enabling patient recruitment.  \n- **Trial objective**: Assess safety, tolerability, and pharmacokinetics of RC220 \u00b1 doxorubicin in solid tumor patients.  \n- **Expansion context**: Follows earlier approvals in Australia (Southside Cancer Centre, Gosford/Wyong Hospitals); additional sites in South Korea anticipated.  \n\n*Note: No direct capital markets or trading impact; operational progress for clinical trial.*",
  "usage": {
    "prompt_tokens": 1833,
    "completion_tokens": 161,
    "total_tokens": 1994,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-09T23:20:54.054338"
}